ITGBL1 and colon adenocarcinoma: Subsequently, we found that patients with higher ITGBL1 expression had shorter overall survival (OS) rates and relapse-free survival (RFS) rates in the TCGA cohort (Figure 1F and G), implying that ITGBL1 was a promising candidate biomarker for predicting the relapse of COAD sufferers.